For example, targeting PPARs has been investigated as an antihyperglycemic medication for treating NAFLD and T2DM; however, the PPARα agonist has only weak effectiveness, or the PPARγ agonist shows undesirable adverse effects, including weight gain [45]. Here, PPARG is linked to type 2 diabetes mellitus.